Experimental KRAS G12D drug slows cancer growth, shrinks tumors in early test
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] SON DAKİKA | Amedspor, Süper Lig’de
- [CONFLICT] Kabine üyelerinden 'Aile ve Nüfus On Yılı Genelgesi' paylaşımı
- [CONFLICT] 1. Lig'de play-off eşleşmeleri belli oldu
- [CONFLICT] İsrail basınından itiraf gibi sözler! "Kendi tuzağımıza düştük"